Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: March 2008
-
March 12, 2008 – Biotechnology, Chemical & Pharmaceutical Art Group Customer Partnership Meeting (U.S. Patent and Trademark Office) March 17, 2008 – Recent Decisions: How They Affect Your Corporate IP Practice (Intellectual Property Owners Association) – Arlington, VA March 30-April 1, 2008 – Advanced Courses (Patent Resources Group) – Bonita Springs, FL March 31-April 1,…
-
By Christopher P. Singer — According to the Office of the Federal Register (OFR), a Notice will publish on Monday, March 10, 2008 relating to "Examination of Patent Applications That Include Claims Containing Alternative Language" (i.e., Markush claim language). While the Notice is currently styled as "Proposed Rules," we note that the U.S.…
-
By Kevin E. Noonan — On Monday, the U.S. District Court for the District of New Jersey (Judge Peter G. Sheridan, presiding) found after a bench trial on all issues that Bayer’s U.S. Patent 6,787,531 was invalid for obviousness. In doing so, the Court’s decision illustrated anew the uncertainties that the U.S. Supreme…
-
By Donald Zuhn — Commonwealth Biotechnologies, Inc. announced today that it has been granted U.S. Patent No. 7,338,761. According to Commonwealth’s press release, while the ‘761 patent is assigned to Vigen Laboratories, the patent is exclusively licensed to CBI Services, a Commonwealth business unit, which developed the claimed invention under contract to Vigen…
-
By Donald Zuhn — Last month, we noted that Millennium Pharmaceuticals spent $1.28 million in 2007 lobbying Congress and the Department of Commerce on patent reform and biologics legislation. Under federal law, lobbyists are required to disclose activities and expenditures that could influence members of the executive and legislative branches. Since the news…
-
As a reminder, the biotechnology, chemical, and pharmaceuticals (BCP) technology groups at the U.S. Patent Office will hold their first quarterly customer partnership meeting of the year on March 12, 2008. The schedule and topics for discussion have been finalized and include: Morning Session • Greetings and Overview (9:00 – 9:15 AM): John LeGuyader, Bruce…
-
By Donald Zuhn — Last week, we reported on appearances by Jon Dudas, the Undersecretary of Commerce for Intellectual Property and Director of U.S. Patent and Trademark Office, and Alan Kasper, the First Vice President of the American Intellectual Property Law Association (AIPLA), at an oversight hearing on the USPTO held by the…
-
By Christopher P. Singer — In an e-Alert sent out on March 4, 2008, the U.S. Patent and Trademark Office provided a link to an updated "Declaration for Utility or Design Patent Application" (Form PTO/SB/01) which can be accessed here. As we previously reported, the updated Declaration form provides a checkbox that automatically…
-
By Donald Zuhn — At last week’s American Conference Institute (ACI) Pharma/Biotech Patent Claim Drafting and Prosecution conference, Bruce Kisliuk, the Director of the U.S. Patent and Trademark Office’s Technology Center 1600, gave an interesting address in which he touched on a number of topics, and then opened the floor to questions from…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. SmithKline Beecham Corporation v. Barr Pharmaceuticals Inc. et al.1:08-cv-00112; filed February 25, 2008 in the District Court of Delaware Infringement of U.S.…
Patent Docs 